Answers are grounded in this paper and cite their sources.
IntroductionStandard therapies for myasthenic crisis (MC) include intravenous immunoglobulin (IVIG) and plasma exchange (PLEx).A subset of patients deteriorates despite these treatments, and conventional immunosuppressants are too slow to address acute crises [1,2].There is a need for alternative rapidly acting agents.Complement activation at the post-synaptic membrane plays a key role in myasthenia gravis (MG) pathogenesis.Zilucoplan is a novel subcutaneous small-molecule inhibitor of complement protein C5, blocking formation of the membrane attack complex [3].Randomized controlled trial (RCT) data confirm its efficacy and tolerability in acetylcholine-receptor (AChR)-positive generalized MG, with clinical improvements observed within the first week of treatment [4].As MC patients were excluded from these trials, the role of zilucoplan in crisis management remains unclear.
No takes yet. Share an insight, caveat, or question.
Lira et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: